Month: November 2022

On April 21, 2011, Bretschneider, Thomas; Voerste, Arnd; Fuesslein, Martin; Koehler, Adeline; Goergens, Ulrich published a patent.Reference of 1-(Pyridin-3-yl)-1H-pyrazole-4-carboxylic acid The title of the patent was Amides and thioamides as pesticides and their preparation. And the patent contained the following:

The invention relates to amides and thioamides of formula I, to a method for the production thereof, and to the use thereof for combating pests. Compounds of formula I wherein G is N, CH, C-halo, C-NO2, C-CN, etc.; R1 is H, alkyl, haloalkyl, cycloalkyl, halo, etc.; X is O and S; R2 is H, alkyl, haloalkyl, alkoxy, etc.; R3 is H, alkyl, haloalkyl, cyanoalkyl, alkenyl, etc.; and their salts and N-oxides thereof, are claimed. Example compound II was prepared by N-arylation of pyrazole-4-carbonitrile with 3-bromopyridine; the resulting 1-(pyridin-3-yl)-1H-pyrazole-4-carbonitrile underwent hydrolysis to give the corresponding carboxylic acid, which underwent chlorination to give the corresponding carboxylic acid chloride hydrochloride, which underwent amidation with ethylamine to give compound II. All the invention compounds were evaluated for their pesticidal activity (some data given). The experimental process involved the reaction of 1-(Pyridin-3-yl)-1H-pyrazole-4-carboxylic acid(cas: 1014631-89-0).Reference of 1-(Pyridin-3-yl)-1H-pyrazole-4-carboxylic acid

The Article related to amide thioamide preparation pesticide, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Reference of 1-(Pyridin-3-yl)-1H-pyrazole-4-carboxylic acid

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On June 24, 2021, Liu, Bo; Cotesta, Simona; Gerspacher, Marc; Leblanc, Catherine; Lorthiois, Edwige Liliane Jeanne; Machauer, Rainer; Mah, Robert; Mura, Christophe; Rigollier, Pascal; Schneider, Nadine; Stutz, Stefan; Vaupel, Andrea; Warin, Nicolas; Wilcken, Rainer published a patent.Product Details of 2089292-88-4 The title of the patent was Pyrazole derivatives as anti-cancer agents and preparation. And the patent contained the following:

The invention relates compounds of formula I, us as anti-cancer agents in the ability to inhibit KRASG12C and their preparation Compound I, wherein A is (un)substituted C5-7, (un)substituted C5-10, (un)substituted 5- to 7-membered unsaturated heterocyclyl containing one carbon-carbon double bond and one oxygen, etc.; B selected from the group of B1 and B2; B1 is (un)substituted C6-10 with 1, 2, 3 and 4 RBa; B2 is 6- to 13-membered heteroaryl containing 1, 2 and 3 nitrogen atoms and is (un)substituted 1, 2, 3 and 4 RBb; each RBa is independently hydroxy, C1-4 alkyl, halo, etc.; each RBb is independently C1-4 alkyl; cyclopropyl, halo, etc.; C is hydrogen, C1-3 alkyl, C3-5 cycloalkyl, etc.; L is (un)substituted 2-azaspiro[3.3]heptanyl, (un)substituted 2-azaspiro[3.4]heptanyl, pyrrolidine, etc.; D is (un)substituted prop-2-en-1-one, (un)substituted prop-2-yn-1-one, etc.; and stereoisomers, atropisomers, pharmaceutically acceptable salts, thereof, are claimed. Conmpound II was prepared using a multistep procedure (procedure given). Compound II was evaluated for KRAS G12C inhibitory activity yielding an IC50 of 0.017μM. Compounds of the invention were evaluated for KRAS G12C inhibitory activity (data given). The experimental process involved the reaction of 5-Bromo-2-methyl-2H-pyrazolo[3,4-c]pyridine(cas: 2089292-88-4).Product Details of 2089292-88-4

The Article related to pyrazole preparation cancer kras inhibition, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Product Details of 2089292-88-4

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On June 24, 2021, Cotesta, Simona; Gerspacher, Marc; Leblanc, Catherine; Liu, Bo; Lorthiois, Edwige Liliane Jeanne; Machauer, Rainier; Mah, Robert; Mura, Christophe; Rigollier, Pascal; Schneider, Nadine; Stutz, Stefan; Vaupel, Andrea; Warin, Nicolas; Wilcken, Rainer published a patent.Formula: C7H6BrN3 The title of the patent was Pyrazolyl derivatives useful as anti-cancer agents. And the patent contained the following:

Pyrazolyl derivatives of formula I [A = cycloalkyl, heterocyclyl, aryl, heteroaryl, etc.; B = aryl, heteroaryl, etc.; C = H, alkyl, cycloalkyl, fluoroalkyl, CN, CH2OH, etc.; L = spirocycloalkyl, etc.; G = COCH=CH2, COCCH, SO2-alkylene, etc.] or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, are prepared as anticancer agents. Thus, (R)-II was prepared, and had IC50 value of 0.017μM in KRASG12C covalent competition assay. The experimental process involved the reaction of 5-Bromo-2-methyl-2H-pyrazolo[3,4-c]pyridine(cas: 2089292-88-4).Formula: C7H6BrN3

The Article related to pyrazolyl derivative preparation anticancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Formula: C7H6BrN3

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On April 20, 2017, Aiguade Bosch, Jose; Connolly, Stephen; Eastwood, Paul Robert; Roberts, Richard Spurring; Sevilla Gomez, Sara; Caturla Javaloyes, Juan Francisco published a patent.Formula: C6H6N4O The title of the patent was Bicyclic heterocycle derivatives as TRPA1 antagonists and their preparation. And the patent contained the following:

The invention relates to bicyclic heterocyclic derivatives of I, to the process for preparing such compounds and to their use in the treatment of pruritus, pain, inflammatory dermatol. diseases, respiratory disorders, gastrointestinal inflammatory disorders, and urinary tract disorders susceptible to amelioration by TRPA1 channel inhibition or antagonism. A compound of formula I wherein G1 is C and N; G2, G3 and G5 are independently N, NRb, CRb and CRc; G4 is absent, N, NRb, CRb and CRc; G6, G7, and G8 are independently N and CRb; G9 and G10 are independently N and NRb; dashed bond is single bond and double bond; L is a bond, CH2, O, S, NRb; m is 0 and 1; Ra is halo, CN, C1-4 haloalkyl, etc; Rb is H and (un)branched C1-4 alkyl group; Rc is H, CN, (un)branched C1-4, etc; and pharmaceutically acceptable salts thereof are claimed. Compound II was prepared from the cross-coupling of 3-[(6-bromo-1H-imidazo[4,5-b]pyrazin-2-yl)methyl]-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one with (4-chlorophenyl)boronic acid. From the assay, it was determined that compound II exhibited an IC50 value in the range of 100 nM – 1000 nM. The experimental process involved the reaction of 1-Methyl-1H-pyrazolo[4,3-d]pyrimidin-7-ol(cas: 314021-93-7).Formula: C6H6N4O

The Article related to bicyclic heterocycle preparation trpa1 antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Triazines and other aspects.Formula: C6H6N4O

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On May 24, 2018, Gavrilov, Aleksey Sergeevich; Aleshunin, Pavel Aleksandrovich; Gorbunova, Svetlana Leonidovna; Rekharsky, Mikhail Vladimirovich; Kozhemyakina, Natalia Vladimirovna; Kukushkina, Anna Aleksandrovna; Kushakova, Anna Sergeevna; Mikhaylov, Leonid Evgen’evich; Moldavsky, Alexander; Popkova, Aleksandra Vladimirovna; Silonov, Sergey Aleksandrovich; Smirnova, Svetlana Sergeevna; Iakovlev, Pavel Andreevich published a patent.Synthetic Route of 924909-16-0 The title of the patent was Pyrazolopyridine and indazole derivatives as inhibitors of Bruton’s tyrosine kinase and their preparation. And the patent contained the following:

The invention relates to a compound of formula I or pharmaceutically acceptable salt, solvate or stereoisomer thereof, which have properties of inhibitor of Bruton’s tyrosine kinase (Btk), to pharmaceutical compositions containing such compounds, and their use as pharmaceuticals for treatment of diseases and disorder. Compounds of formula I wherein V1 is C and N; V2 is CR2 and N; M is absent and CH2; K is absent and LR3; L is CH2, NH, O and a bond; R1 is (un)substituted 4-(4-oxo-4H-pyridin-1-yl)aryl, (un)substituted 4-(aryloxy)aryl, (un)substituted 4-(arylaminocarbonyl)aryl, etc.; R2 and R11 are independently H, D,halo, CN, C1-6 alkoxy, etc.; R3 is H, halo, CN, OH, C1-6 alkyl, etc.; R6 is N-substituted azetidin-3-yl, N-substituted pyrrolidinyl, and N-substituted piperidin-3-yl; and pharmaceutically acceptable salts, solvates, and stereoisomers thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). The invention compounds were evaluated for their BTK inhibitory activity (data given). The experimental process involved the reaction of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol(cas: 924909-16-0).Synthetic Route of 924909-16-0

The Article related to pyrazolopyridine indazole preparation bth inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Synthetic Route of 924909-16-0

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On March 5, 2020, Hinklin, Ronald Jay; Allen, Shelley; Barbour, Patrick; Cook, Adam; Dahlke, Joshua; Gaudino, John; Laird, Ellen; Mcnulty, Oren T.; Zhao, Qian published a patent.Quality Control of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol The title of the patent was Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases and their preparation. And the patent contained the following:

Provided herein are compounds of the formula I and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor. Compounds of formula I wherein X1 is CH2 and N; R1 is H and C1-6 alkyl; R2 is H, C1-6 alkyl, C1-6 hydroxyalkyl, (un)substituted 3- to 4-membered cycloalkyl, etc.; R9 is H and halo; G is (un)substituted 5- to 6-membered oxoheterocyclyl and (un)substituted oxoquinolinyl; and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by N-(3-fluoro-4-((3-iodo-1-(4-methoxybenzyl)-lH-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide with ethanolamine; the resulting N-(3-fluoro-4-((3-((2-hydroxyethyl)amino)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide underwent hydrolysis to give compound II. The invention compounds were evaluated for their TAM and MET kinase inhibitory activity (data given). The experimental process involved the reaction of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol(cas: 924909-16-0).Quality Control of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol

The Article related to pyrazolopyridine preparation tam met kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Quality Control of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On September 30, 1993, Hichour, M.; Mary, F.; Marzin, C.; Naji, M.; Tarrago, G. published an article.Category: pyrazoles-derivatives The title of the article was N-Alkylation of pyrazolones with OH-protection. And the article contained the following:

The synthesis of biheterocyclic compound I containing two pyrazolone sub-units is described. The oxygen atom of 3-carbethoxypyrazol-5-one is first protected with dihydropyran to obtain selective alkylation with 1-3-dibromopropane. The experimental process involved the reaction of Ethyl 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate(cas: 153597-59-2).Category: pyrazoles-derivatives

The Article related to pyrazolonecarboxylate protection alkylation dibromopropane, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Category: pyrazoles-derivatives

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On April 3, 2014, Wilson, Kevin J.; Witter, David J.; Daniels, Matthew H.; Angeles, Angie R.; Siliphaivanh, Phieng; Sloman, David; O’Boyle, Brendan; Falcone, Danielle; White, Catherine; Ferguson, Ron; Zhou, Wei; Lipford, Kathryn; Mansoor, Umar Faruk; Fevrier, Salem; Huang, Xianhai; Kurukulasuriya, Ravi; Richard, Judson E.; Tang, Shuyi; Boyce, Christopher; Kozlowski, Joseph; Bakshi, Raman Kumar; Karunakaran, Ganesh Babu published a patent.Electric Literature of 215610-30-3 The title of the patent was Preparation of pyrazolopyridinyl ureas as ERK inhibitors. And the patent contained the following:

The title compounds I [R1 = OR4, S(O)tR5; t = 0-2; R2 = H, alkyl; alkyl-O-alkyl, alkylaryl, etc.; R4 = alkyl-O-alkyl, alkylaryl, etc.; R5 = alkyl, alkyl-O-alkyl; R10, R11 = H, halo, alkyl, etc.] which are ERK inhibitors useful in treating cancer, were prepared E.g., a multi-step synthesis of (1R)-II, starting from Me 4,6-dichloropyridine-3-carboxylate and hydrazine, was described. Exemplified compounds I were tested in human ERK2 activity assay (data given). Pharmaceutical compositions comprising compound I, alone or in combination with an effective amount of at least one chemotherapeutic agent, were disclosed. The experimental process involved the reaction of 5-Methoxy-1H-pyrazole(cas: 215610-30-3).Electric Literature of 215610-30-3

The Article related to pyrazolopyridinyl urea preparation erk inhibitor antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Electric Literature of 215610-30-3

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On September 7, 2021, Cho, Won Je published a patent.Name: 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde The title of the patent was Preparation of pyrazolecarboxamide for preventing or treating metabolic disease. And the patent contained the following:

The present invention relates to a novel pyrazolecarboxamide carboxamide compound I [R1 = H, 3-OMe, 3,4-(OMe)2, 4-Me; R2 = H, CF3, NH2; OR3 = meta-(3-pyridinyloxy), para-(4-isopropylphenyl), para-(2-methoxy-4-methylphenyl), etc.] and a composition for preventing or treating metabolic diseases, wherein the composition is a potent and selective estrogen-related receptor (ERR) γ inverse agonist with excellent selectivity and since it shows affinity, it can be effectively used for treatment of metabolic diseases. For example, II was prepared and exhibited IC50 of 1.33μM against estrogen-related receptor (ERR) γ. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Name: 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde

The Article related to preparation pyrazolecarboxamide treatment metabolic disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Name: 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On February 4, 2020, Wang, Renxiao; Liu, Hong; Yu, Biao; Li, Yangfeng; Li, Chunpiao; Li, Yan; Zhou, Mi; Li, Qing; Su, Minyi published a patent.Application of 36640-53-6 The title of the patent was Phenyl pyrazole compound, its pharmaceutical composition, preparing method and application. And the patent contained the following:

The invention relates to Ph pyrazole compounds of formula I and II, their preparation and application as Bcl inhibitor. Compounds I and II, wherein Ra is R1(O)n(CH2)m; R1 is C6-14 aryl or substituted C6-14 aryl; m is 0-6; n is 0 or 1; R is H or C1-C4 alkyl; Rb and Rc are independently H, C3-C8 cycloalkyl, C1-C6 alkyl, etc.; their stereoisomers, or pharmaceutically acceptable salts, are claimed. The inventive compound can be applied in preparing the drugs for preventing and/or treating Bcl-related diseases or preparing Bcl inhibitor, with high activity and low toxicity. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Application of 36640-53-6

The Article related to phenyl pyrazole preparation bcl inhibitor treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Application of 36640-53-6

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics